Vanda Pharmaceuticals (VNDA) Capital Leases (2024 - 2026)

Vanda Pharmaceuticals' Capital Leases history runs 3 years deep, the most recent figure standing at $3.8 million for Q1 2026.

• In Q1 2026, Capital Leases rose 28.44% year-over-year to $3.8 million; the TTM figure through Mar 2026 stood at $3.8 million (up 28.44% YoY), while the FY2025 annual figure was $4.1 million, up 29.56% from the prior year.
• Capital Leases came in at $3.8 million for Q1 2026 at Vanda Pharmaceuticals, down from $4.1 million in the prior quarter.
• In the past five years, Capital Leases ranged from a high of $4.1 million in Q4 2025 to a low of $2.8 million in Q3 2025.
• A 3-year average of $3.3 million and a median of $3.1 million in 2024 frame the typical range for Capital Leases.
• Across the five-year window, Capital Leases grew 29.56% in 2025 and rose 28.44% in 2026, its largest moves.
• Vanda Pharmaceuticals' Capital Leases stood at $3.1 million in 2024, then gained by 29.56% to $4.1 million in 2025, then declined by 7.14% to $3.8 million in 2026.
• According to Business Quant data, Capital Leases over the past three periods registered $3.8 million, $4.1 million, and $2.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison